Profit before interest, taxes and amortization: 10x Genomics (TXG)
10x Genomics, Inc. (TXG) is protected by a powerful patent portfolio in the field of spatial biology. The business is independent of macroeconomic trends, serving as a reliable defensive asset. The operating cash flow on GURU.Markets reflects profit dynamics, where the value of 0.00 shows the most recent figure. 10x Genomics, Inc. (TXG) minimizes risks by supplying cancer research and neurobiology equipment to leading research centers.
Summary analytical data breakdowns for 10x Genomics (TXG)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- book capitalization data:
- debt level and financial liquidity data:
Total Debt to Equity Ratio 10x Genomics, Inc.|TXG - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient 10x Genomics Inc|TXG - Company Total Debt|Debt to Net Assets Ratio 10x Genomics|TXG - Company Long-Term Debts|Short-Term Debt Volume 10x Genomics|Immediate Liquidity Ratio 10xgenomics.com
- earnings and multiples data:
TXG - Net Profit|Future Profit 10x Genomics, Inc.|TXG - Price to Earnings Ratio|Market Cap to Projected Earnings 10xgenomics.com|TXG - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio 10x Genomics|TXG - Operating profit before deduction of amortization|Earnings per share for the last 12 months 10x Genomics|TXG - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year 10xgenomics.com|TXG - Earnings growth in current year|Projected earnings per share growth rate for next year 10x Genomics, Inc.
Fundamental company valuation:10x
Monitoring the sustainability of operating cash flow is critical for long-term risk management. The specific nature of 10x Genomics, Inc. (TXG) requires immense expenditures to retain scarce bioinformaticians and R&D staff. An analysis of actual EBITDA allows for an assessment of core business profitability before the impact of taxes and interest. This chart demonstrates management's ability to maintain margins despite rising costs for highly qualified personnel. The stability of this metric confirms the fundamental strength of the business model.
Who 10x Genomics, Inc. competes with
TEM: Operating profit before amortization|QGEN - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization ionispharma.com|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Avidity Biosciences Inc|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|GeneDx Corp (WGS) - Operating income before deduction of amortization|Operating profit EBITDA RARE|Operating profit before deduction of amortization beamtx.com BEAM|Profit before payment of interest, taxes and amortization Sarepta SRPT|Operating income before deduction of amortization Twist Bioscience Inc (TWST)|NTLA: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization STOK (Stoke Corp)|BLFS: Operating profit EBITDA|WVE - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Maze Therapeutics|Operating profit before amortization SION (Sionna Therapeutics, Inc.)|Operating profit EBITDA PRME|Operating profit before deduction of amortization Taysha Corp TSHA|uniQure N.V. - Operating profit before deduction of amortization|Operating income before deduction of amortization meiragtx.com (MGTX)|RGNX: Operating profit before deduction of amortization|Solid Biosciences Inc - Company profit before taxes, interest and amortization|OCGN (Ocugen Corp) - Operating profit before deduction of amortization|Operating profit before amortization PACB|BNTC (Benitec Biopharma Inc.) - Operating profit EBITDA|DSGN - Operating profit before depreciation charges|Operating profit EBITDA RCKT|4DMT - Operating profit before amortization|Profit before payment of interest, taxes and amortization Lexeo Therapeutics, Inc. LXEO|KRRO: Operating profit before amortization|Editas Medicine, Inc. - Operating profit EBITDA|SLN - Operating profit EBITDA|PRQR: Operating profit EBITDA|CDXS: Company profit before taxes, interest and amortization|Operating profit before deduction of amortization SGMO|Operating profit before amortization NAUT (Nautilus Biotechnology Inc)|Operating profit before deduction of amortization MGX (Metagenomi, Inc.)|DTIL (precisionbiosciences.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA GBIO (Generation Bio)|Operating profit before depreciation charges Boundless Bio Inc.|Exicure Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Imunon, Inc.|phiopharma.com (PHIO) - Profit before payment of interest, taxes and amortization|Operating profit before amortization MBIO|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Profit before interest, taxes and amortization Bionano BNGO|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|Operating profit before deduction of amortization bluebird bio, Inc BLUE|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|Operating income before deduction of amortization omegatherapeutics.com (OMGA)|Singular Genomics - Operating profit EBITDA|Regulus Therapeutics, Inc. (RGLS) - Operating profit before deduction of amortization|Syros (SYRS) - Profit before payment of interest, taxes and amortization|TBIO - Operating income before deduction of amortization|Operating profit before deduction of amortization TCON|UBX: Income before deduction of interest, taxes and amortization
